Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research
  • Published:

High Yield Production and Purification of Recombinant Staphylokinase for Thrombolytic Therapy

Bio/Technology volume 12, pages 185–189 (1994)Cite this article

Abstract

Recombinant plasmids were constructed in which the signal sequence of the sak42D and the sakSTAR staphylokinase genes were replaced by an ATG start codon and which express staphylokinase under the control of a tac promoter and two Shine–Dalgarno sequences in tandem. Induction of transfected E. coli TGI cells in a bacterial fermentor produced intracellular staphylokinase representing 10 to 15% of total cell protein, Gram quantities of highly purified recombinant staphylokinase were obtained from cytosol fractions by chromatography, at room temperature, on SP–Sepharose and on phehyl–Sepharose columns, with yields of 50 to 70 percent. The material, at a dose of 4 mg/kg, did not produce acute reactions or affect body weight in mice. Intravenous administration of 10 mg SakSTAR over 30 minutes in five patients with acute myocardial infarction induced complete coronary artery recanaiization, without associated fibrinogen degradation. However, neutralizing antibodies appeared in the plasma of all patients within 12 to 20 days. Thus, the present expression and purification method for recombinant staphylokinase yields large amounts of highly purified mature protein (approximately 200 mg per liter fermentation broth) suitable for a more detailed clinical investigation of its potential as a thrombolytic agent.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Collen, D. and Lijnen, H.R. 1991. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114–3124.

    CAS  Google Scholar 

  2. The GUSTO Investigators. 1993. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl. J. Med. 329: 673–682.

  3. Lack, C.H. 1948. Staphylokinase: An activator of plasma protease. Nature 161: 559–560.

    Article  CAS  Google Scholar 

  4. Kowalska-Loth, B. and Zakrzewski, K. 1975. The activation by staphylokinase of human plasminogen. Acta Biochim. Pol. 22: 327–339.

    CAS  PubMed  Google Scholar 

  5. Ericson, R. 1977. The mechanism of activation of plasminogen by staphylokinase. Chem. Abstr. 86: 202 (Abstract 67386Z).

    Google Scholar 

  6. Collen, D., Schlott, B., Engelborghs, Y., Van Hoef, B., Hartmann, M., Lijnen, H.R. and Behnke, D. 1993. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J. Biol. Chem. 268: 8284–8289.

    CAS  Google Scholar 

  7. Lijnen, H.R., Van Hoef, B., De Cock, F., Okada, K., Ueshima, S., Matsuo, O. and Collen, D. 1991. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J. Biol. Chem. 266: 11826–11832.

    CAS  Google Scholar 

  8. Matsuo, O., Okada, K., Fukao, H., Tomioka, Y., Ueshima, S., Watanuki, M. and Sakai, M. 1990. Thrombolytic properties of staphylokinase. Blood 76: 925–929.

    CAS  PubMed  Google Scholar 

  9. Sakai, M., Watanuki, M. and Matsuo, O. 1989. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α-2plasmin inhibitor. Biochem. Biophys. Res. Comm. 162: 830–837.

    Article  CAS  Google Scholar 

  10. Silence, K., Collen, D. and Lijnen, H.R. 1993. Interaction between staphylokinase, plasmin(ogen) and α2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by α2-antiplasmin. J. Biol. Chem. 268: 9811–9816.

    CAS  PubMed  Google Scholar 

  11. Collen, D. and Van de Werf,, F. 1993. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 87: 1850–1853.

    Article  CAS  Google Scholar 

  12. Collen, D., Silence, K., Demarsin, E., De Mol, M. and Lijnen, H.R. 1992. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 6: 203–213.

    Article  CAS  Google Scholar 

  13. Lewis, J.H., Kerber, C.W. and Wilson, J.H. 1964. The effects of fibrinolytic agents and heparin on intravascular clotlysis. Amer. J. Physiol. 207: 1044–1048.

    CAS  PubMed  Google Scholar 

  14. Sako, T., Sawaki, S., Sakurai, T., Ito, S., Yoshizawa, Y. and Kondo, I. 1983. Cloning and expression of the staphylokinase gene of Staphylococcus aureusin Escherichia coli. Molec. Gen. Genet. 190: 271–277.

    Article  CAS  Google Scholar 

  15. Behnke, D. and Gerlach, D. 1987. Cloning and expression in Escherichia coli, Bacillus subtilis and Streptococcus sanguis of a gene for staphylokinase—a bacterial plasminogen activator. Molec. Gen. Genet. 210: 528–534.

    Article  CAS  Google Scholar 

  16. Sako, T. 1985. Overproduction of staphylokinase in Escherichia coli and its characterization. Eur. J. Biochem. 149: 557–563.

    Article  CAS  Google Scholar 

  17. Collen, D., Zhao, Z.A., Holvoet, P. and Marynen, P. 1992. Primary structure and gene structure of staphylokinase. Fibrinolysis. 6: 226–231.

    Article  CAS  Google Scholar 

  18. Riesenberg, D., Schulz, V., Knorre, W.A., Pohl, H.D., Korz, D., Sanders, E., Ross, A. and Deckwer, D. 1991. High cell density cultivation of Escherichia coli at controlled specific growth rate. J. Biotechnol. 20: 17–28.

    Article  CAS  Google Scholar 

  19. Collen, D., De Mol, M., Demarsin, E., De Cock, F. and Stassen, J.M. 1993. Isolation and conditioning of recombinant staphylokinase for use in man. Fibrinolysis 7: 242–247.

    Article  CAS  Google Scholar 

  20. Stassen, J.M., Vanlinthout, I., Lijnen, H.R. and Collen, D. 1990. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharma-cokinetic properties of thrombolytic agents. Fibrinolysis 4:(Suppl 2): 15–21.

    Article  CAS  Google Scholar 

  21. Collen, D., De Cock, F., Vanlinthout, I., Declerck, P.J., Lijnen, H.R. and Stassen, J.M. 1992. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 6: 232–242.

    Article  CAS  Google Scholar 

  22. Collen, D., De Cock, F. and Stassen, J.M. 1993. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87: 996–1006.

    Article  CAS  Google Scholar 

  23. Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, New York.

  24. Sanger, F., Nicklen, S. and Coulson, A.R. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74: 5463–5467.

    Article  CAS  Google Scholar 

  25. Bradford, M.M. 1976. A rapid and sensitive method for the quantisation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Désiré Collen: Corresponding author.

Authors and Affiliations

  1. Institute for Molecular Biotechnology, 0-6900, Jena, Germany

    Bernhard Schlott, Manfred Hartmann, Karl-Heinz Gührs, Eckhard Birch-Hirschfeid & Detlev Behnke

  2. Hans Knoll Institute, 0-6900, Jena, Germany

    Hans-Dieter Pohl

  3. Center for Molecular and Vascular Biology, University of Leuven, Leuven, B-3000, Belgium

    Steven Vanderschueren & Désiré Collen

  4. Laboratory for Experimental Cardiology, University of Leuven, Leuven, B-3000, Belgium

    Frans Van de Werf

  5. Laboratory for Galenic and Clinical Pharmacy, University of Leuven, Leuven, B-3000, Belgium

    Armand Michoel

Authors
  1. Bernhard Schlott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manfred Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karl-Heinz Gührs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eckhard Birch-Hirschfeid
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hans-Dieter Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven Vanderschueren
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Frans Van de Werf
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Armand Michoel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Désiré Collen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Detlev Behnke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlott, B., Hartmann, M., Gührs, KH. et al. High Yield Production and Purification of Recombinant Staphylokinase for Thrombolytic Therapy. Nat Biotechnol 12, 185–189 (1994). https://doi.org/10.1038/nbt0294-185

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0294-185

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing